Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.

Name:	us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Topic 852
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 10
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481372/852-10-55-10

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 946
-SubTopic 210
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-04(18))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(30)(a)(1))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

SCHEDULE OF RESTATEMENT CONSOLIDATED FINANCIAL STATEMENTS (Details) - USD ($)	Sep. 30, 2025	Jun. 30, 2025	Mar. 31, 2025	Feb. 17, 2025	Dec. 31, 2024	Sep. 30, 2024	Jun. 30, 2024	Mar. 31, 2024	Dec. 31, 2023	Dec. 30, 2023
Current Assets:
Cash	$ 1,948,271				$ 3,633
Total current assets	2,403,129				147,989
TOTAL ASSETS	2,403,129				147,989
Current Liabilities:
Other Current Liabilities				$ 353,679	111,026
Total current liabilities	13,860,506				1,688,077
TOTAL LIABILITIES	13,870,407				1,688,077
Stockholders Equity:
Common stock - Par Value $0.001	4,953				2,760
Additional paid-in-capital	11,078,116				1,234,385
Accumulated Deficit	(22,550,347)				(2,777,233)
TOTAL SHAREHOLDERS’ DEFICIT	(11,467,278)	$ (9,616,785)	$ (7,952,742)		(1,540,088)	$ (774,378)	$ (558,109)	$ (489,747)	$ (487,861)	$ (487,861)
TOTAL LIABILITIES AND SHAREHOLDERS’ DEFICIT	$ 2,403,129				147,989
Aspire Biopharma Inc [Member]
Current Assets:
Cash					3,633				11,174
Total current assets					147,989				46,174
TOTAL ASSETS					147,989				46,174
Current Liabilities:
Short-term loans from shareholders					1,266,832				360,636
Other Current Liabilities					111,026				626
Total current liabilities					1,688,077				534,035
TOTAL LIABILITIES					1,688,077				534,035
Stockholders Equity:
Common stock - Par Value $0.001					22,000				22,000
Additional paid-in-capital					1,215,113				957,500
Accumulated Deficit					(2,777,233)				(1,467,361)
TOTAL SHAREHOLDERS’ DEFICIT					(1,540,088)				(487,861)
TOTAL LIABILITIES AND SHAREHOLDERS’ DEFICIT					$ 147,989				46,174
Previously Reported [Member] \| Aspire Biopharma Inc [Member]
Current Assets:
Cash									11,174
Prepaid Expenses									35,000
Total current assets									46,174
TOTAL ASSETS									46,174
Current Liabilities:
Accounts Payable									172,773
Short-term loans from shareholders									360,636
Other Current Liabilities									626
Total current liabilities									534,035
TOTAL LIABILITIES									534,035
Stockholders Equity:
Common stock - Par Value $0.001									221,500
Additional paid-in-capital									758,000
Accumulated Deficit									(1,467,361)
TOTAL SHAREHOLDERS’ DEFICIT									(487,861)
TOTAL LIABILITIES AND SHAREHOLDERS’ DEFICIT									46,174
Revision of Prior Period, Adjustment [Member] \| Aspire Biopharma Inc [Member]
Current Assets:
Cash									11,174
Prepaid Expenses									35,000
Total current assets									46,174
TOTAL ASSETS									46,174
Current Liabilities:
Accounts Payable									172,773
Short-term loans from shareholders									360,636
Other Current Liabilities									626
Total current liabilities									534,035
TOTAL LIABILITIES									534,035
Stockholders Equity:
Common stock - Par Value $0.001									22,000
Additional paid-in-capital									957,500
Accumulated Deficit									(1,467,361)
TOTAL SHAREHOLDERS’ DEFICIT									(487,861)
TOTAL LIABILITIES AND SHAREHOLDERS’ DEFICIT									46,174
Revision of Prior Period, Reclassification, Adjustment [Member] \| Aspire Biopharma Inc [Member]
Current Assets:
Cash
Prepaid Expenses
Total current assets
TOTAL ASSETS
Current Liabilities:
Accounts Payable
Short-term loans from shareholders
Other Current Liabilities
Total current liabilities
TOTAL LIABILITIES
Stockholders Equity:
Common stock - Par Value $0.001									(199,500)
Additional paid-in-capital									199,500
Accumulated Deficit
TOTAL SHAREHOLDERS’ DEFICIT
TOTAL LIABILITIES AND SHAREHOLDERS’ DEFICIT